Possible scenario
Smooth Commercial Launch
42% Chance
The expanded partnership translates into a well-coordinated US rollout for Moderna and Merck's individualized melanoma vaccine, using Tempus for patient identification, sequencing, and oncology workflow support. This is the base case because Phase 3 success and Tempus' 100,000-genome dataset make Tempus a credible commercialization infrastructure partner.
Secondary impacts
- Healthcare +0.5%
- Technology +0.1%
Tickers
- TEM+6.3%
- MRNA+2.9%
- PSNL+1.5%
- MRK+1.0%
Portfolio impact
S&P 500+0.1%
Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.
Keeping an eye on this scenario?
Tilt can alert you when its probability or impact shifts, or send you a recommendation when it crosses a threshold.